Ownership rights to tissue donated for research end when the tissue leaves the body, as does all claim to benefit from commercial cell lines or other products derived from the tissue.
Specific advocate guidelines are needed for the protection of children in state custody who are potential research subjects in trials that would expose them to greater-than-minimal risk but also hold the prospect of direct benefit.
Dr Noah Boton joins Ethics Talk to discuss his article, coauthored with Dr Jeffrey Larnard: “When Should Patients at the End of Life Get Antimicrobials?”
Dr Jeannie P. Cimiotti joins Ethics Talk to discuss her article, coauthored with Drs Kimberly Adams Tufts, Lucia D. Wocial, and Elizabeth Peter: “How Should Focus Be Shifted From Individual Preference to Collective Wisdom for Patients at the End of Life With Antimicrobial-Resistant Infections?”
A bioethicist argues that children with Down syndrome should not be subjected to cosmetic surgery to change their appearance unless they are at the age and have the capacity to make the decision for themselves.
Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
In “Ethics of International Research: What Does Responsiveness Mean?” Christine Grady explains how developing countries are vulnerable to exploitation by researchers and explores what “responsiveness” to the needs of those populations might entail.
A physician argues that pharmaceutical industry support for residency programs creates a conflict of interest and compromises the educational integrity of the programs.